STTK Shattuck Labs Inc

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in a fireside chat and one-on-one meetings at BTIG’s Virtual Biotechnology Conference, taking place August 5-6, 2024.

Presentation DetailsConference: BTIG Virtual Biotechnology ConferenceFormat: Fireside chat with covering analyst, Kaveri Pohlman, Ph.D.Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: August 5, 2024Time: 2:00 p.m. ET

A live webcast of the fireside chat will be available to conference participants. If you are interested in meeting with the Shattuck team during the conference, please reach out to your BTIG representative.

About Shattuck Labs, Inc.Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary ARC® platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor & Media Contact: Conor RichardsonVice President of Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com